Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/14770
Title
Targeting the MAPK Pathway in KRAS-Driven Tumors.
Author(s)
Drosten, Matthias CNIO | Barbacid, Mariano CNIO
Date issued
2020-04-13
Citation
Cancer Cell . 2020;37(4):543-550.
Language
Inglés
Document type
journal article
Abstract
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we review recent efforts to validate individual components of the mitogen-activated protein kinase (MAPK) pathway as targets to treat KRAS-mutant cancers by comparing genetic information derived from experimental mouse models of KRAS-driven lung and pancreatic tumors with the outcome of selective MAPK inhibitors in clinical trials. We also review the potential of RAF1 as a key target to block KRAS-mutant cancers.
MESH
Molecular Targeted Therapy | Mutation | Humans | Mitogen-Activated Protein Kinases | Neoplasms | Protein Kinase Inhibitors | Proto-Oncogene Proteins p21(ras)
Online version
DOI
Collections
Files in this item
- Name:
- targetingthemapkpathway_2020.pdf
- Size:
- 955.5Kb
- Format:
- Description:
- Artículo principal